缺氧相关长链非编码RNA作为肝癌预后预测标志物的潜在价值

doi:10.16288/j.yczz.21-416

遗传 ›› 2022, Vol. 44 ›› Issue (2): 153-167.doi: 10.16288/j.yczz.21-416

缺氧相关长链非编码RNA作为肝癌预后预测标志物的潜在价值

程敏^1,³(), 张静⁴, 曹鹏博²(), 周钢桥^1,^2,³()

1. 南京医科大学公共卫生学院流行病学系,南京 211166
2. 军事科学院军事医学研究院辐射医学研究所,蛋白质组学国家重点实验室,国家蛋白质科学中心,北京 100850
3. 南京医科大学全球健康中心,南京 211166
4. 河北大学生命科学学院,保定 071002

收稿日期:2021-12-02 修回日期:2022-01-11 出版日期:2022-02-20 发布日期:2022-01-19
通讯作者: 曹鹏博,周钢桥 E-mail:18351990262@139.com;birchcpb@163.com;zhougq114@126.com
作者简介:程敏,硕士研究生,专业方向：流行病与卫生统计学。E-mail: 18351990262@139.com
基金资助:
国家重点研发计划编号(2017YFA0504301);国家自然科学基金重大研究计划重点项目资助编号(91440206)

Prognostic and predictive value of the hypoxia-associated long non-coding RNA signature in hepatocellular carcinoma

Min Cheng^1,³(), Jing Zhang⁴, Pengbo Cao²(), Gangqiao Zhou^1,^2,³()

1. Department of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing 211166, China
2. State Key Lab of Proteomics, National Center for Protein Sciences at Beijing, Institute of Radiation Medicine, Academy of Military Medical Sciences, Academy of Military Sciences, Beijing 100850, China
3. Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing 211166, China
4. College of Life Science, Hebei University, Baoding 071002, China

Received:2021-12-02 Revised:2022-01-11 Online:2022-02-20 Published:2022-01-19
Contact: Cao Pengbo,Zhou Gangqiao E-mail:18351990262@139.com;birchcpb@163.com;zhougq114@126.com
Supported by:
Supported by the National Key Research and Development Program of China No(2017YFA0504301);the Major Research Plan of the National Natural Science Foundation of China No(91440206)

摘要/Abstract

摘要：

肝细胞癌(hepatocellular carcinoma, 简称肝癌)是一种常见的恶性肿瘤。缺氧是肝癌等实体肿瘤的一个重要特征,同时也是诱导肿瘤恶性进展的重要因素。然而,肝癌缺氧相关的长链非编码RNA(long non-coding RNA,lncRNA)的鉴定及其在临床生存预后等方面的价值仍未得到系统的研究。本研究旨在通过肝癌转录组的整合分析鉴定肝癌缺氧相关的lncRNA,并评估其在肝癌预后中的价值。基于癌症基因组图谱(The Cancer Genome Atlas, TCGA)计划的肝癌转录组数据的整合分析,初步鉴定到233个缺氧相关的候选lncRNA。进一步筛选具有预后价值的候选者,基于其中12个缺氧相关lncRNA (AC012676.1、PRR7-AS1、AC020915.2、AC008622.2、AC026401.3、MAPKAPK5-AS1、MYG1-AS1、AC015908.3、AC009275.1、MIR210HG、CYTOR和SNHG3)建立了肝癌预后风险模型。Cox比例风险回归分析显示,基于该模型计算的缺氧风险评分作为肝癌患者新的独立预后预测指标,优于传统的临床病理因素。基因集富集分析显示,缺氧风险评分反映了细胞增殖相关通路的活化和脂代谢过程的失活。综上所述,本研究构建了一个基于缺氧相关lncRNA的风险评分模型,可以作为肝癌患者预后预测的候选指标,并初步提示了这些缺氧相关的lncRNA在肝癌防治中的重要作用。

关键词: 肝细胞癌, 缺氧, 长链非编码RNA, 预后模型

Abstract:

Hepatocellular carcinoma (HCC) is a common cancer worldwide. Hypoxia is an important feature of solid tumors, including HCC, and is also an important factor involved in malignancy progression. However, the identification of hypoxia-related long non-coding RNA (lncRNAs) and their prognostic value in HCC have not been systematically investigated. The aim of this study is to identify the features based on the hypoxia-related lncRNAs and evaluate their predictive value for HCC prognosis. Based on the integrated analysis of HCC transcriptome data from The Cancer Genome Atlas (TCGA), we had identified 233 potential hypoxia-related lncRNAs. We further evaluated the prognostic value of these lncRNAs and optimally established a 12-lncRNA (AC012676.1, PRR7-AS1, AC020915.2, AC008622.2, AC026401.3, MAPKAPK5-AS1, MYG1-AS1, AC015908.3, AC009275.1, MIR210HG, CYTOR and SNHG3) prognostic risk model. The Cox proportional hazards regression analysis revealed that the hypoxia risk score is a novel independent prognostic predictor for HCC patients, which outperforms the traditional clinical pathological factors. Gene set enrichment analysis (GSEA) showed that the hypoxia risk score reflects the activation of biological features related to cell proliferation and the inactivation of lipid metabolism processes. In summary, we had constructed a risk score model based on 12 hypoxia-related lncRNAs, which might be a promising prognostic predictor for HCC patients and highlight their potential roles in the prevention and treatment of this malignancy.

Key words: hepatocellular carcinoma, hypoxia, long non-coding RNA, prognostic model

程敏, 张静, 曹鹏博, 周钢桥. 缺氧相关长链非编码RNA作为肝癌预后预测标志物的潜在价值[J]. 遗传, 2022, 44(2): 153-167.

Min Cheng, Jing Zhang, Pengbo Cao, Gangqiao Zhou. Prognostic and predictive value of the hypoxia-associated long non-coding RNA signature in hepatocellular carcinoma[J]. Hereditas(Beijing), 2022, 44(2): 153-167.

图/表 15

图1

图2

图3

图4

图5

图6

附表1

附表2

附表3

附表4

附表4

续"

基因集	基因集大小	NES	P
GO_OXYGEN_BINDING	47	-1.67	0
GO_ARACHIDONIC_ACID_MONOOXYGENASE_ACTIVITY	15	-1.66	0
GO_PEROXISOME_ORGANIZATION	32	-2.00	0.0020
GO_PROTEIN_DEGLYCOSYLATION	21	-1.97	0.0020
GO_REGULATION_OF_TRIGLYCERIDE_METABOLIC_PROCESS	32	-1.90	0.0020
GO_SERINE_FAMILY_AMINO_ACID_METABOLIC_PROCESS	41	-1.89	0.0020
GO_2_OXOGLUTARATE_METABOLIC_PROCESS	20	-1.88	0.0020
GO_REGULATION_OF_TRIGLYCERIDE_BIOSYNTHETIC_PROCESS	17	-1.88	0.0020
GO_CELLULAR_AMINO_ACID_CATABOLIC_PROCESS	111	-1.87	0.0020
GO_ALPHA_AMINO_ACID_CATABOLIC_PROCESS	94	-1.87	0.0020
GO_PYRIDOXAL_PHOSPHATE_BINDING	51	-1.86	0.0020
GO_SULFUR_AMINO_ACID_METABOLIC_PROCESS	40	-1.84	0.0020
GO_REGULATION_OF_CHOLESTEROL_METABOLIC_PROCESS	22	-1.84	0.0020
GO_ACYL_COA_DEHYDROGENASE_ACTIVITY	17	-1.82	0.0020
GO_GLYOXYLATE_METABOLIC_PROCESS	27	-1.81	0.0020
GO_REGULATION_OF_MITOCHONDRIAL_FISSION	17	-1.73	0.0020
GO_ENERGY_RESERVE_METABOLIC_PROCESS	72	-1.68	0.0020
GO_BILE_ACID_TRANSMEMBRANE_TRANSPORTER_ACTIVITY	15	-1.66	0.0020
GO_SULFUR_AMINO_ACID_BIOSYNTHETIC_PROCESS	19	-1.86	0.0021
GO_REGULATION_OF_GLUCOSE_METABOLIC_PROCESS	104	-1.80	0.0021
GO_BLOOD_COAGULATION_INTRINSIC_PATHWAY	17	-1.77	0.0021
GO_ORGANIC_HYDROXY_COMPOUND_TRANSPORT	155	-1.67	0.0021
GO_OXIDOREDUCTASE_ACTIVITY_ACTING_ON_PAIRED_DONORS_WITH_INCORPORATION_OR_REDUCTION_OF_MOLECULAR_OXYGEN_REDUCED_FLAVIN_OR_FLAVOPROTEIN_AS_ONE_DONOR_AND_INCORPORATION_OF_ONE_ATOM_OF_OXYGEN	26	-1.65	0.0021
GO_FATTY_ACYL_COA_BINDING	30	-1.87	0.0039
GO_FATTY_ACID_BETA_OXIDATION_USING_ACYL_COA_DEHYDROGENASE	18	-1.79	0.0040
GO_BILE_ACID_AND_BILE_SALT_TRANSPORT	31	-1.76	0.0040
GO_GLUCAN_METABOLIC_PROCESS	58	-1.75	0.0040
GO_REGULATION_OF_LIPID_CATABOLIC_PROCESS	50	-1.74	0.0040
GO_CELLULAR_LIPID_CATABOLIC_PROCESS	148	-1.84	0.0041
GO_SMALL_MOLECULE_CATABOLIC_PROCESS	325	-1.83	0.0041
GO_OXIDOREDUCTASE_ACTIVITY_ACTING_ON_PAIRED_DONORS_WITH_INCORPORATION_OR_REDUCTION_OF_MOLECULAR_OXYGEN	149	-1.75	0.0041
GO_RESPONSE_TO_XENOBIOTIC_STIMULUS	104	-1.74	0.0041
GO_OXIDOREDUCTASE_ACTIVITY_ACTING_ON_PAIRED_DONORS_WITH_INCORPORATION_OR_REDUCTION_OF_MOLECULAR_OXYGEN_NAD_P_H_AS_ONE_DONOR_AND_INCORPORATION_OF_ONE_ATOM_OF_OXYGEN	36	-1.73	0.0041
GO_BLOOD_COAGULATION_FIBRIN_CLOT_FORMATION	24	-1.73	0.0041
GO_DRUG_TRANSMEMBRANE_TRANSPORT	19	-1.68	0.0041
GO_GLUTAMATE_METABOLIC_PROCESS	28	-1.69	0.0042
GO_ALPHA_AMINO_ACID_METABOLIC_PROCESS	226	-1.80	0.0060
GO_PROTEIN_ACTIVATION_CASCADE	67	-1.78	0.0060

附表4

附表4

续"

基因集	基因集大小	NES	P
GO_ALDEHYDE_DEHYDROGENASE_NAD_ACTIVITY	19	-1.72	0.0060
GO_ANDROGEN_METABOLIC_PROCESS	30	-1.72	0.0062
GO_TRANSCRIPTION_FACTOR_ACTIVITY_DIRECT_LIGAND_REGULATED_SEQUENCE_ SPECIFIC_DNA_BINDING	48	-1.67	0.0062
GO_BRANCHED_CHAIN_AMINO_ACID_METABOLIC_PROCESS	23	-1.78	0.0079
GO_MANNOSIDASE_ACTIVITY	15	-1.76	0.0079
GO_REACTIVE_NITROGEN_SPECIES_METABOLIC_PROCESS	19	-1.76	0.0079
GO_STEROL_TRANSPORT	50	-1.69	0.0081
GO_GLYCINE_METABOLIC_PROCESS	17	-1.68	0.0082
GO_MONOCARBOXYLIC_ACID_TRANSMEMBRANE_TRANSPORTER_ACTIVITY	45	-1.64	0.0083
GO_STEROID_METABOLIC_PROCESS	232	-1.78	0.0085
GO_S_ADENOSYLMETHIONINE_METABOLIC_PROCESS	18	-1.73	0.010
GO_CELLULAR_AMINO_ACID_BIOSYNTHETIC_PROCESS	91	-1.73	0.010
GO_FATTY_ACID_METABOLIC_PROCESS	287	-1.70	0.010
GO_TRANSMEMBRANE_RECEPTOR_PROTEIN_SERINE_THREONINE_KINASE_ACTIVITY	17	-1.68	0.010
GO_BENZENE_CONTAINING_COMPOUND_METABOLIC_PROCESS	24	-1.68	0.010
GO_REGULATION_OF_GLUCONEOGENESIS	37	-1.81	0.012
GO_ALPHA_AMINO_ACID_BIOSYNTHETIC_PROCESS	75	-1.73	0.012
GO_MONOCARBOXYLIC_ACID_METABOLIC_PROCESS	491	-1.71	0.012
GO_THIOESTER_METABOLIC_PROCESS	83	-1.70	0.012
GO_PROTEIN_LIPID_COMPLEX	39	-1.70	0.012
GO_PLATELET_DENSE_GRANULE	20	-1.71	0.013
GO_ARGININE_METABOLIC_PROCESS	17	-1.66	0.013
GO_CELLULAR_AMINO_ACID_METABOLIC_PROCESS	328	-1.75	0.014
GO_REGULATION_OF_CELLULAR_KETONE_METABOLIC_PROCESS	170	-1.68	0.014
GO_TRICARBOXYLIC_ACID_METABOLIC_PROCESS	37	-1.82	0.016
GO_ASPARTATE_FAMILY_AMINO_ACID_METABOLIC_PROCESS	55	-1.80	0.016
GO_REGULATION_OF_PROTEIN_ACTIVATION_CASCADE	34	-1.76	0.016
GO_NEGATIVE_REGULATION_OF_MITOCHONDRION_ORGANIZATION	39	-1.71	0.016
GO_POSITIVE_REGULATION_OF_TRIGLYCERIDE_METABOLIC_PROCESS	20	-1.71	0.017
GO_RESPONSE_TO_MERCURY_ION	15	-1.69	0.017
GO_REGULATION_OF_FATTY_ACID_METABOLIC_PROCESS	85	-1.65	0.017
GO_STEROL_HOMEOSTASIS	57	-1.77	0.019
GO_STEROL_METABOLIC_PROCESS	121	-1.71	0.019
GO_REGULATION_OF_LIPOPROTEIN_LIPASE_ACTIVITY	15	-1.64	0.019
GO_MITOCHONDRIAL_MATRIX	406	-1.84	0.020
GO_DICARBOXYLIC_ACID_METABOLIC_PROCESS	99	-1.73	0.020
GO_PROTEIN_HOMOTETRAMERIZATION	59	-1.73	0.020
GO_COMPLEMENT_ACTIVATION	45	-1.67	0.020
GO_POSITIVE_REGULATION_OF_LIPID_CATABOLIC_PROCESS	25	-1.69	0.021
GO_COFACTOR_METABOLIC_PROCESS	329	-1.66	0.024

附表4

附表5

参考文献 57

[1]	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin, 2015, 65(2): 87-108.S doi: 10.3322/caac.21262
[2]	Yuen VW, Wong CC. Hypoxia-inducible factors and innate immunity in liver cancer. J Clin Invest, 2020, 130(10):5052-5062. doi: 10.1172/JCI137553
[3]	Shimamoto K, Tanimoto K, Fukazawa T, Nakamura H, Kanai A, Bono H, Ono H, Eguchi H, Hirohashi N. GLIS1, a novel hypoxia-inducible transcription factor, promotes breast cancer cell motility via activation of WNT5A. Carcinogenesis, 2020, 41(9):1184-1194. doi: 10.1093/carcin/bgaa010 pmid: 32047936
[4]	Huang JL, Zheng L, Hu YW, Wang Q. Characteristics of long non-coding RNA and its relation to hepatocellular carcinoma. Carcinogenesis, 2014, 35(3):507-514. doi: 10.1093/carcin/bgt405
[5]	Standaert L, Adriaens C, Radaelli E, Van Keymeulen A, Blanpain C, Hirose T, Nakagawa S, Marine JC. The long noncoding RNA Neat1 is required for mammary gland development and lactation. RNA, 2014, 20(12):1844-1849. doi: 10.1261/rna.047332.114 pmid: 25316907
[6]	Wang Y, Chen WY, Lian JY, Zhang HB, Yu B, Zhang MJ, Wei FQ, Wu JH, Jiang JX, Jia YS, Mo F, Zhang SR, Liang XD, Mou XZ, Tang JM. The lncRNA PVT1 regulates nasopharyngeal carcinoma cell proliferation via activating the KAT2A acetyltransferase and stabilizing HIF-1α. Cell Death Differ, 2020, 27(2):695-710. doi: 10.1038/s41418-019-0381-y
[7]	Wang XW, Li L, Zhao KM, Lin QY, Li HY, Xue XT, Ge WJ, He HJ, Liu D, Xie H, Wu Q, Hu Y. A novel LncRNA HITT forms a regulatory loop with HIF-1α to modulate angiogenesis and tumor growth. Cell Death Differ, 2020, 27(4):1431-1446. doi: 10.1038/s41418-019-0449-8
[8]	Zeng Z, Xu FY, Zheng H, Cheng P, Chen QY, Ye Z, Zhong JX, Deng SJ, Liu ML, Huang K, Li Q, Li W, Hu YH, Wang F, Wang CY, Zhao G. LncRNA-MTA2TR functions as a promoter in pancreatic cancer via driving deacetylation-dependent accumulation of HIF-1α. Theranostics, 2019, 9(18):5298-5314. doi: 10.7150/thno.34559 pmid: 31410216
[9]	Deng SJ, Chen HY, Ye Z, Deng SC, Zhu S, Zeng Z, He C, Liu ML, Huang K, Zhong JX, Xu FY, Li Q, Liu Y, Wang CY, Zhao G. Hypoxia-induced LncRNA-BX111 promotes metastasis and progression of pancreatic cancer through regulating ZEB1 transcription. Oncogene, 2018, 37(44):5811-5828. doi: 10.1038/s41388-018-0382-1
[10]	Liang YR, Song XJ, Li YM, Chen B, Zhao WJ, Wang LJ, Zhang HW, Liu Y, Han DW, Zhang N, Ma TT, Wang YJ, Ye FZ, Luo D, Li XY, Yang QF. LncRNA BCRT1 promotes breast cancer progression by targeting miR-1303/PTBP3 axis. Mol Cancer, 2020, 19(1):85. doi: 10.1186/s12943-020-01206-5
[11]	Dong L, Cao X, Luo Y, Zhang GQ, Zhang DD. A positive feedback loop of lncRNA DSCR8/miR-98-5p/STAT3/HIF- 1α plays a role in the progression of ovarian cancer. Front Oncol, 2020, 10:1713. doi: 10.3389/fonc.2020.01713
[12]	Hua Q, Mi BM, Xu F, Wen J, Zhao L, Liu JJ, Huang G. Hypoxia-induced lncRNA-AC020978 promotes proliferation and glycolytic metabolism of non-small cell lung cancer by regulating PKM2/HIF-1α axis. Theranostics, 2020, 10(11):4762-4778. doi: 10.7150/thno.43839
[13]	Winter SC, Buffa FM, Silva P, Miller C, Valentine HR, Turley H, Shah KA, Cox GJ, Corbridge RJ, Homer JJ, Musgrove B, Slevin N, Sloan P, Price P, West CM, Harris AL. Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers. Cancer Res, 2007, 67(7):3441-3449. doi: 10.1158/0008-5472.CAN-06-3322
[14]	Eustace A, Mani N, Span PN, Irlam JJ, Taylor J, Betts GNJ, Denley H, Miller CJ, Homer JJ, Rojas AM, Hoskin PJ, Buffa FM, Harris AL, Kaanders JHAM, West CML. A 26-gene hypoxia signature predicts benefit from hypoxia- modifying therapy in laryngeal cancer but not bladder cancer. Clin Cancer Res, 2013, 19(17):4879-4888. doi: 10.1158/1078-0432.CCR-13-0542 pmid: 23820108
[15]	Hänzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics, 2013, 14:7. doi: 10.1186/1471-2105-14-7 pmid: 23323831
[16]	Sun ZL, Jing CY, Xiao CT, Li TC. An autophagy-related long non-coding RNA prognostic signature accurately predicts survival outcomes in bladder urothelial carcinoma patients. Aging (Albany NY), 2020, 12(15):15624-15637.
[17]	Steyerberg EW, Vergouwe Y. Towards better clinical prediction models: seven steps for development and an ABCD for validation. Eur Heart J, 2014, 35(29):1925-1931. doi: 10.1093/eurheartj/ehu207 pmid: 24898551
[18]	Blanche P, Dartigues JF, Jacqmin-Gadda H. Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks. Stat Med, 2013, 32(30):5381-5397. doi: 10.1002/sim.5958 pmid: 24027076
[19]	Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA, 2005, 102(43):15545-15550. doi: 10.1073/pnas.0506580102
[20]	Zhang CJ, Zheng YX, Li X, Hu X, Qi F, Luo J. Genome-wide mutation profiling and related risk signature for prognosis of papillary renal cell carcinoma. Ann Transl Med, 2019, 7(18):427. doi: 10.21037/atm
[21]	Tang FZ, Li CW, Kang BX, Gao G, Li C, Zhang ZM. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res, 2017, 45(W1):W98-W102. doi: 10.1093/nar/gkx247
[22]	Kim S, Kang D, Huo ZG, Park Y, Tseng GC. Meta- analytic principal component analysis in integrative omics application. Bioinformatics, 2018, 34(8):1321-1328. doi: 10.1093/bioinformatics/btx765
[23]	Tang R, Wu JC, Zheng LM, Li ZR, Zhou KL, Zhang ZS, Xu DF, Chen C. Long noncoding RNA RUSC1-AS-N indicates poor prognosis and increases cell viability in hepatocellular carcinoma. Eur Rev Med Pharmacol Sci, 2018, 22(2):388-396.
[24]	Torgovnick A, Schumacher B. DNA repair mechanisms in cancer development and therapy. Front Genet, 2015, 6:157.
[25]	Fasanaro P, Greco S, Ivan M, Capogrossi MC, Martelli F. microRNA: emerging therapeutic targets in acute ischemic diseases. Pharmacol Ther, 2010, 125(1):92-104. doi: 10.1016/j.pharmthera.2009.10.003
[26]	Feng S, He AB, Wang DL, Kang B. Diagnostic significance of miR-210 as a potential tumor biomarker of human cancer detection: an updated pooled analysis of 30 articles. Onco Targets Ther, 2019, 12:479-493. doi: 10.2147/OTT
[27]	Kim JH, Park SG, Song SY, Kim JK, Sung JH. Reactive oxygen species-responsive miR-210 regulates proliferation and migration of adipose-derived stem cells via PTPN2. Cell Death Dis, 2013, 4(4):e588. doi: 10.1038/cddis.2013.117
[28]	Yang W, Sun T, Cao JP, Liu FJ, Tian Y, Zhu W. Downregulation of miR-210 expression inhibits proliferation, induces apoptosis and enhances radiosensitivity in hypoxic human hepatoma cells in vitro. Exp Cell Res, 2012, 318(8):944-954. doi: 10.1016/j.yexcr.2012.02.010 pmid: 22387901
[29]	Ying Q, Liang LH, Guo WJ, Zha RP, Tian Q, Huang SL, Yao J, Ding J, Bao MY, Ge C, Yao M, Li JJ, He XH. Hypoxia-inducible microRNA-210 augments the metastatic potential of tumor cells by targeting vacuole membrane protein 1 in hepatocellular carcinoma. Hepatology, 2011, 54(6):2064-2075. doi: 10.1002/hep.24614
[30]	Wu H, Wang T, Liu YQ, Li X, Xu SL, Wu CT, Zou HB, Cao MF, Jin GX, Lang JY, Wang B, Liu BH, Luo XL, Xu C. Mitophagy promotes sorafenib resistance through hypoxia-inducible ATAD3A dependent axis. J Exp Clin Cancer Res, 2020, 39(1):274. doi: 10.1186/s13046-020-01768-8
[31]	Ebright RY, Zachariah MA, Micalizzi DS, Wittner BS, Niederhoffer KL, Nieman LT, Chirn B, Wiley DF, Wesley B, Shaw B, Nieblas-Bedolla E, Atlas L, Szabolcs A, Iafrate AJ, Toner M, Ting DT, Brastianos PK, Haber DA, Maheswaran S. HIF1A signaling selectively supports proliferation of breast cancer in the brain. Nat Commun, 2020, 11(1):6311. doi: 10.1038/s41467-020-20144-w
[32]	Lin YT, Wu KJ. Epigenetic regulation of epithelial- mesenchymal transition: focusing on hypoxia and TGF-β signaling. J Biomed Sci, 2020, 27(1):39. doi: 10.1186/s12929-020-00632-3
[33]	Wang XX, Che XF, Yu Y, Cheng Y, Bai M, Yang ZC, Guo QQ, Xie XC, Li DN, Guo M, Hou KZ, Guo WD, Qu XJ, Cao L. Hypoxia-autophagy axis induces VEGFA by peritoneal mesothelial cells to promote gastric cancer peritoneal metastasis through an integrin α5-fibronectin pathway. J Exp Clin Cancer Res, 2020, 39(1):221. doi: 10.1186/s13046-020-01703-x
[34]	Ramapriyan R, Caetano MS, Barsoumian HB, Mafra ACP, Zambalde EP, Menon H, Tsouko E, Welsh JW, Cortez MA. Altered cancer metabolism in mechanisms of immunotherapy resistance. Pharmacol Ther, 2019, 195:162-171. doi: 10.1016/j.pharmthera.2018.11.004
[35]	Chen BW, Zhou Y, Wei T, Wen L, Zhang YB, Shen SC, Zhang J, Ma T, Chen W, Ni L, Wang Y, Bai XL, Liang TB. lncRNA-POIR promotes epithelial-mesenchymal transition and suppresses sorafenib sensitivity simultaneously in hepatocellular carcinoma by sponging miR-182-5p. J Cell Biochem, 2021, 122(1):130-142. doi: 10.1002/jcb.v122.1
[36]	Sun Z, Xue SL, Zhang MY, Xu H, Hu XM, Chen SH, Liu YY, Guo MZ, Cui HM. Aberrant NSUN2-mediated m(5)C modification of H19 lncRNA is associated with poor differentiation of hepatocellular carcinoma. Oncogene, 2020, 39(45):6906-6919. doi: 10.1038/s41388-020-01475-w
[37]	Cai HY, Zhang Y, Zhang HY, Cui C, Li CH, Lu SC. Prognostic role of tumor mutation burden in hepatocellular carcinoma after radical hepatectomy. J Surg Oncol, 2020, 121(6):1007-1014. doi: 10.1002/jso.v121.6
[38]	Maleki Vareki S. High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors. J Immunother Cancer, 2018, 6(1):157. doi: 10.1186/s40425-018-0479-7 pmid: 30587233
[39]	Liu GM, Zeng HD, Zhang CY, Xu JW. Identification of a six-gene signature predicting overall survival for hepatocellular carcinoma. Cancer Cell Int, 2019, 19:138. doi: 10.1186/s12935-019-0858-2
[40]	Li XY, Jin F, Li Y. A novel autophagy-related lncRNA prognostic risk model for breast cancer. J Cell Mol Med, 2021, 25(1):4-14. doi: 10.1111/jcmm.v25.1
[41]	Li XY, Li Y, Yu XM, Jin F. Identification and validation of stemness-related lncRNA prognostic signature for breast cancer. J Transl Med, 2020, 18(1):331. doi: 10.1186/s12967-020-02497-4
[42]	Jin LP, Li CY, Liu T, Wang L. A potential prognostic prediction model of colon adenocarcinoma with recurrence based on prognostic lncRNA signatures. Hum Genomics, 2020, 14(1):24. doi: 10.1186/s40246-020-00270-8
[43]	Niklasson CU, Fredlund E, Monni E, Lindvall JM, Kokaia Z, Hammarlund EU, Bronner ME, Mohlin S. Hypoxia inducible factor-2α importance for migration, proliferation, and self-renewal of trunk neural crest cells. Dev Dyn, 2021, 250(2):191-236. doi: 10.1002/dvdy.v250.2
[44]	Liu OH, Kiema M, Beter M, Ylä-Herttuala S, Laakkonen JP, Kaikkonen MU. Hypoxia-mediated regulation of histone demethylases affects angiogenesis-associated functions in endothelial cells. Arterioscler Thromb Vasc Biol, 2020, 40(11):2665-2677. doi: 10.1161/ATVBAHA.120.315214
[45]	Renfrow JJ, Soike MH, West JL, Ramkissoon SH, Metheny-Barlow L, Mott RT, Kittel CA, D'agostino Jr RB, Tatter SB, Laxton AW, Frenkel MB, Hawkins GA, Herpai D, Sanders S, Sarkaria JN, Lesser GJ, Debinski W, Strowd RE. Attenuating hypoxia driven malignant behavior in glioblastoma with a novel hypoxia-inducible factor 2 alpha inhibitor. Sci Rep, 2020, 10(1):15195. doi: 10.1038/s41598-020-72290-2 pmid: 32938997
[46]	Yu AJ, Zhao LW, Kang QM, Li J, Chen K, Fu H. Transcription factor HIF1α promotes proliferation, migration, and invasion of cholangiocarcinoma via long noncoding RNA H19/microRNA-612/Bcl-2 axis. Transl Res, 2020, 224:26-39. doi: 10.1016/j.trsl.2020.05.010
[47]	Wang L, Sun LK, Liu RY, Mo HY, Niu YS, Chen TX, Wang YF, Han SS, Tu KS, Liu QG. Long non-coding RNA MAPKAPK5-AS1/PLAGL2/HIF-1α signaling loop promotes hepatocellular carcinoma progression. J Exp Clin Cancer Res, 2021, 40(1):72. doi: 10.1186/s13046-021-01868-z
[48]	Hu B, Yang XB, Yang X, Sang XT. LncRNA CYTOR affects the proliferation, cell cycle and apoptosis of hepatocellular carcinoma cells by regulating the miR-125b-5p/KIAA1522 axis. Aging (Albany NY), 2020, 13(2):2626-2639.
[49]	Wei F, Wang Y, Zhou Y, Li Y. Long noncoding RNA CYTOR triggers gastric cancer progression by targeting miR-103/RAB10. Acta Biochim Biophys Sin (Shanghai), 2021, 53(8):1044-1054. doi: 10.1093/abbs/gmab071
[50]	Yang JL, Ma Q, Zhang MM, Zhang WF. LncRNA CYTOR drives L-OHP resistance and facilitates the epithelial- mesenchymal transition of colon carcinoma cells via modulating miR-378a-5p/SERPINE1. Cell Cycle, 2021, 20(14):1415-1430. doi: 10.1080/15384101.2021.1934626
[51]	Wang Y, Li WJ, Chen XY, Li Y, Wen PH, Xu F. MIR210HG predicts poor prognosis and functions as an oncogenic lncRNA in hepatocellular carcinoma. Biomed Pharmacother, 2019, 111:1297-1301. doi: S0753-3322(18)37945-9 pmid: 30841443
[52]	He ZY, Dang J, Song AL, Cui X, Ma ZJ, Zhang ZT. Identification of LINC01234 and MIR210HG as novel prognostic signature for colorectal adenocarcinoma. J Cell Physiol, 2019, 234(5):6769-6777. doi: 10.1002/jcp.v234.5
[53]	Ma J, Kong FF, Yang D, Yang H, Wang CC, Cong R, Ma XX. LncRNA MIR210HG promotes the progression of endometrial cancer by sponging miR-337-3p/137 via the HMGA2-TGF-β/Wnt pathway. Mol Ther Nucleic Acids, 2021, 24:905-922. doi: 10.1016/j.omtn.2021.04.011
[54]	Bu L, Zhang LB, Tian M, Zheng ZB, Tang HJ, Yang QJ. LncRNA MIR210HG facilitates non-small cell lung cancer progression through directly regulation of miR-874/STAT3 axis. Dose Response, 2020, 18(3):1559325820918052.
[55]	Wang AH, Jin CH, Cui GY, Li HY, Wang Y, Yu JJ, Wang RF, Tian XY. MIR210HG promotes cell proliferation and invasion by regulating miR-503-5p/TRAF4 axis in cervical cancer. Aging (Albany NY), 2020, 12(4):3205-3217.
[56]	Yu TZ, Li GP, Wang CG, Gong GQ, Wang LW, Li CY, Chen Y, Wang XL. MIR210HG regulates glycolysis, cell proliferation, and metastasis of pancreatic cancer cells through miR-125b-5p/HK2/PKM2 axis. RNA Biol, 2021, 18(12):2513-2530. doi: 10.1080/15476286.2021.1930755
[57]	Du Y, Wei N, Ma RL, Jiang SH, Song D. Long noncoding RNA MIR210HG promotes the warburg effect and tumor growth by enhancing HIF-1α translation in triple-negative breast cancer. Front Oncol, 2020, 10:580176. doi: 10.3389/fonc.2020.580176

编辑推荐

Metrics

www.chinagene.cn
备案号：京ICP备09063187号-4
总访问:,今日访问:,当前在线:

特征	样本量(n=367)	比例(%)
年龄(岁)
> 60	194	52.9
≤ 60	173	47.1
性别
女	119	32.4
男	248	67.6
T分类
T1(< 2厘米)	181	49.3
T2(2~5厘米)	92	25.1
T3(≥ 5厘米)	78	21.3
T4(靠近肝脏的血管和/或器官和/或内脏腹膜侵犯)	13	3.5
NA	3	0.8
N分类
N0(附近的淋巴结没有癌细胞)	249	67.8
N1(肝脏附近淋巴结的癌细胞)	4	1.1
NA	114	31.1
M分类
M0(没有癌细胞已经扩散到肝外的迹象)	264	71.9
M1(癌细胞存在于身体其他器官,如肺部或骨骼)	3	0.8
NA	100	27.3

MTX1	ADORA2B	AK3	ALDOA	ANGPTL4	C20orf20	MRPS17	PGF	PGK1
P4HA1	PFKFB4	PGAM1	PVR	SLC16A1	SLC2A1	TEAD4	TPBG	TPI1
GAPD	GMFB	GSS	HES2	HIG2	IL8	KCTD11	KRT17	PEDS1
PSMA7	PSMB7	PSMD2	PTGFRN	PYGL	RAN	RNF24	RNPS1	RUVBL2
ANLN	VEGF	LOC56901	S100A3	B4GALT2	VEZT	LRP2BP	SIP1	BCAR1
MGC14560	SLC6A10	BMS1L	ANKRD9	MGC17624	SLC6A8	BNIP3	C14orf156	MGC2408
HOMER1	C15orf25	MIF	SMILE	HSPC163	CA12	MRPL14	SNX24	IMP-2
NUDT15	SPTB	KIAA1393	LDHA	LDLR	MGC2654	MNAT1	NDRG1	NME1
COL4A5	CORO1C	CTEN	DKFZP564D166	DPM2	EIF2S1	PAWR	PDZK11	PLAU
PPARD	PPP2CZ	PPP4R1	TFAP2C	TIMM23	TMEM30B	TPD52L2	VAPB	XPO5
ANLN	BNC1	C20orf20	CA9	CDKN3	COL4A6	DCBLD1	ENO1	FAM83B
GNAI1	HIG2	KCTD11	KRT17	LDHA	MPRS17	P4HA1	PGAM1	PGK1
AFARP1	TUBB2	LOC149464	S100A10	AD-003	SLCO1B3	CA9	CDCA4	PLEKHG3
ALDOA	FOSL1	SDC1	SLC16A1	SLC2A1	TPI1	VEGFA

LncRNA	Rho	HR (95% CI)	P	类型
AC004816.1	0.6042	1.83 (1.29~2.60)	0.00076	风险
AC008622.2	0.8633	2.37 (1.66~3.40)	< 0.0001	风险
AC009275.1	0.6005	1.82 (1.28~2.59)	0.00083	风险
AC012676.1	0.7518	2.12 (1.49~3.02)	< 0.0001	风险
AC015908.3	-0.7035	0.49 (0.35~0.71)	0.0001	保护
AC020915.2	0.7523	2.12 (1.48~3.04)	< 0.0001	风险
AC026401.3	0.6128	1.85 (1.30~2.63)	0.00068	风险
AC073573.1	-0.6068	0.55 (0.38~0.78)	0.00093	保护
AC114803.1	0.9514	2.59 (1.81~3.71)	< 0.0001	风险
CYTOR	0.7993	2.22 (1.56~3.18)	< 0.0001	风险
DANCR	0.7093	2.03 (1.43~2.90)	< 0.0001	风险
GIHCG	0.7331	2.08 (1.46~2.97)	< 0.0001	风险
MAFG.DT	0.5451	1.72 (1.22~2.44)	0.0022	风险
MAPKAPK5-AS1	0.9134	2.49 (1.73~2.59)	< 0.0001	风险
MIR210HG	0.7222	2.06 (1.44~2.95)	< 0.0001	风险
MIR4435.2HG	0.6980	2.01 (1.41~2.86)	0.00011	风险
MYG1-AS1	0.5395	1.72 (1.21~2.43)	0.0025	风险
PRR7-AS1	0.8126	2.25 (1.59~3.19)	< 0.0001	风险
SNHG3	0.6218	1.86 (1.31~2.65)	0.00054	风险
TMEM220-AS1	-0.4673	0.63 (0.44~0.89)	0.0089	保护

基因	正义(5′→3′)	反义 (5′→3′)
MIR210HG	TGAGTAGGAACTCTGGGCGA	CCACAATGGGAAGGAGGCAT
HIF1A	AGAGGTTGAGGGACGGAGAT	GCACCAAGCAGGTCATAGGT
TGFB	GTCTCCCAAGGAAAGGTAGG	CTCTTGAGTCCCTCGCATCC
AKT	GCGGCAGGACCGAGC	AGGTCTTGATGTACTCCCCTCG
VEGFA	GTCCTGGAGCGTGTACGTTG	CTTCCGGGCTCGGTGATTTA
ACTIN	AGAGCCTCGCCTTTGCCGAT	AGAGCCTCGCCTTTGCCGAT

缺氧相关长链非编码RNA作为肝癌预后预测标志物的潜在价值

Prognostic and predictive value of the hypoxia-associated long non-coding RNA signature in hepatocellular carcinoma

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 15

参考文献 57

相关文章 13

编辑推荐

Metrics

基因集	基因集大小	NES	P
GO_RETROGRADE_VESICLE_MEDIATED_TRANSPORT_GOLGI_TO_ER	77	2.34	0
GO_NEGATIVE_REGULATION_OF_MITOTIC_CELL_CYCLE	198	1.82	0
GO_REGULATION_OF_PROTEASOMAL_UBIQUITIN_DEPENDENT_PROTEIN_CATABOLIC_ PROCESS	146	1.81	0
GO_POSITIVE_REGULATION_OF_CELL_CYCLE_PROCESS	243	1.81	0
GO_NUCLEAR_CHROMOSOME_SEGREGATION	218	1.81	0
GO_TUBULIN_BINDING	263	1.78	0
GO_MICROTUBULE_BASED_MOVEMENT	199	1.77	0
GO_MICROTUBULE	397	1.77	0
GO_SPINDLE_MIDZONE	27	1.81	0.0020
GO_REGULATION_OF_CELL_DIVISION	266	1.80	0.0021
GO_NEGATIVE_REGULATION_OF_ORGANELLE_ORGANIZATION	384	1.77	0.0021
GO_REGULATION_OF_DNA_DEPENDENT_DNA_REPLICATION	41	1.81	0.0040
GO_NUCLEAR_UBIQUITIN_LIGASE_COMPLEX	42	1.81	0.0041
GO_POSITIVE_REGULATION_OF_G1_S_TRANSITION_OF_MITOTIC_CELL_CYCLE	24	1.78	0.0041
GO_CONDENSED_CHROMOSOME	183	1.77	0.0043

基因集	基因集大小	NES	P
GO_RECOMBINATIONAL_REPAIR	70	1.78	0.0063
GO_CONDENSED_CHROMOSOME_CENTROMERIC_REGION	94	1.78	0.0064
GO_POSITIVE_REGULATION_OF_MITOTIC_NUCLEAR_DIVISION	51	1.77	0.0064
GO_SPINDLE_ASSEMBLY	68	1.81	0.0081
GO_HETEROCHROMATIN	66	1.77	0.0083
GO_CELL_CYCLE_G2_M_PHASE_TRANSITION	132	1.81	0.0084
GO_MITOTIC_CELL_CYCLE_CHECKPOINT	138	1.80	0.013
GO_SPINDLE_LOCALIZATION	38	1.78	0.014
GO_POSITIVE_REGULATION_OF_CHROMOSOME_SEGREGATION	25	1.77	0.014
GO_MEMBRANE_DISASSEMBLY	46	1.79	0.021
GO_REGULATION_OF_TELOMERE_MAINTENANCE	62	1.81	0.023
GO_CHROMOSOMAL_REGION	310	1.79	0.023
GO_SPLICEOSOMAL_COMPLEX	163	1.78	0.033
GO_RNA_SPLICING	335	1.79	0.038
GO_LIPID_OXIDATION	68	-2.15	0
GO_MICROBODY	132	-2.13	0
GO_FATTY_ACID_CATABOLIC_PROCESS	71	-2.13	0
GO_FATTY_ACID_BETA_OXIDATION	49	-2.10	0
GO_MICROBODY_PART	92	-2.08	0
GO_COENZYME_BINDING	175	-2.07	0
GO_ORGANIC_ACID_CATABOLIC_PROCESS	202	-2.03	0
GO_FLAVIN_ADENINE_DINUCLEOTIDE_BINDING	73	-2.02	0
GO_MICROBODY_MEMBRANE	58	-2.00	0
GO_METHIONINE_METABOLIC_PROCESS	18	-1.99	0
GO_COFACTOR_BINDING	258	-1.97	0
GO_MICROBODY_LUMEN	44	-1.97	0
GO_AMINO_ACID_BETAINE_METABOLIC_PROCESS	18	-1.94	0
GO_LIPID_HOMEOSTASIS	107	-1.89	0
GO_BILE_ACID_METABOLIC_PROCESS	35	-1.89	0
GO_REGULATION_OF_FATTY_ACID_OXIDATION	27	-1.84	0
GO_BILE_ACID_BIOSYNTHETIC_PROCESS	20	-1.82	0
GO_CELLULAR_ALDEHYDE_METABOLIC_PROCESS	83	-1.82	0
GO_ACYLGLYCEROL_HOMEOSTASIS	29	-1.82	0
GO_MONOOXYGENASE_ACTIVITY	91	-1.80	0
GO_DRUG_METABOLIC_PROCESS	39	-1.78	0
GO_POSITIVE_REGULATION_OF_FATTY_ACID_METABOLIC_PROCESS	33	-1.78	0
GO_NITROGEN_CYCLE_METABOLIC_PROCESS	15	-1.75	0
GO_STEROID_HYDROXYLASE_ACTIVITY	31	-1.70	0
GO_IRON_ION_BINDING	158	-1.70	0
GO_EPOXYGENASE_P450_PATHWAY	18	-1.69	0

基因集	基因集大小	NES	P
GO_OXIDOREDUCTASE_ACTIVITY_ACTING_ON_THE_CH_CH_GROUP_OF_DONORS	57	-1.77	0.025
GO_QUATERNARY_AMMONIUM_GROUP_TRANSPORT	18	-1.74	0.025
GO_SIGNAL_PEPTIDE_PROCESSING	24	-1.71	0.027
GO_GLUCAN_BIOSYNTHETIC_PROCESS	25	-1.68	0.027
GO_RETROGRADE_TRANSPORT_VESICLE_RECYCLING_WITHIN_GOLGI	23	-1.72	0.028
GO_NAD_BINDING	53	-1.69	0.029
GO_NUCLEOSIDE_BISPHOSPHATE_METABOLIC_PROCESS	37	-1.70	0.030
GO_ENDOCYTIC_VESICLE_LUMEN	17	-1.64	0.030
GO_LIGASE_ACTIVITY_FORMING_CARBON_SULFUR_BONDS	40	-1.65	0.035
GO_TRIGLYCERIDE_RICH_LIPOPROTEIN_PARTICLE	19	-1.65	0.035
GO_ASPARTATE_FAMILY_AMINO_ACID_BIOSYNTHETIC_PROCESS	23	-1.66	0.036
GO_COENZYME_A_METABOLIC_PROCESS	17	-1.65	0.041
GO_2_IRON_2_SULFUR_CLUSTER_BINDING	21	-1.65	0.044

[1]	熊婉迪, 徐开宇, 陆林, 李家立. 长链非编码RNA在阿尔茨海默病中的研究进展[J]. 遗传, 2022, 44(3): 189-197.
[2]	雷常贵, 贾学渊, 孙文靖. 基于癌症基因组图谱计划多组学数据构建胶质母细胞瘤六基因预后模型[J]. 遗传, 2021, 43(7): 665-679.
[3]	骆红波, 曹鹏博, 周钢桥. DNA甲基化驱动的转录表达特征作为肝癌预后预测标志物的价值[J]. 遗传, 2020, 42(8): 775-787.
[4]	张华伟, 孟星宇, 李连峰, 杨玉莹, 仇华吉. 长链非编码RNA——抗病毒天然免疫应答的新兴调控因子[J]. 遗传, 2018, 40(7): 525-533.
[5]	邹俊遐, 陈科. 缺氧诱导因子(HIFs)在肾癌发生中的作用及其分子机制[J]. 遗传, 2018, 40(5): 341-356.
[6]	周瑞,王以鑫,龙科任,蒋岸岸,金龙. LncRNA调控骨骼肌发育的分子机制及其在家养动物中的研究进展[J]. 遗传, 2018, 40(4): 292-304.
[7]	路畅, 黄银花. 动物长链非编码RNA研究进展[J]. 遗传, 2017, 39(11): 1054-1065.
[8]	李静秋, 杨杰, 周平, 乐燕萍, 龚朝辉. 竞争性内源RNA的生物学功能及其调控[J]. 遗传, 2015, 37(8): 756-764.
[9]	黄小庆,李丹丹,吴娟. 植物长链非编码RNA研究进展[J]. 遗传, 2015, 37(4): 344-359.
[10]	杨峰, 易凡, 曹慧青, 梁子才, 杜权. 长链非编码RNA研究进展[J]. 遗传, 2014, 36(5): 456-468.
[11]	李灵, 宋旭. 长链非编码RNA在生物体中的调控作用[J]. 遗传, 2014, 36(3): 228-236.
[12]	樊春燕, 魏强, 郝志强, 李广林. miRNAs调控lincRNAs的生物信息学预测与功能分析[J]. 遗传, 2014, 36(12): 1226-1234.
[13]	夏天，肖丙秀，郭俊明. 长链非编码RNA的作用机制及其研究方法[J]. 遗传, 2013, 35(3): 269-280.